Todd C. Davis

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
La Jolla, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Todd C. Davis

Form 4 holding Director

Vaxart, Inc.

Security class
Common Stock
Shares / value
125,905
Estimated value
$300,913
Report date
04 Aug 2022
Price
$2.39
Ownership
Direct
Form 4 holding Director

Channel Therapeutics Corp

Security class
Series A Convertible Preferred Stock
Shares / value
3,127,868
Estimated value
Report date
01 Jul 2025
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director

LIGAND PHARMACEUTICALS INC

Security class
Employee Stock Option (right to buy)
Shares / value
50,058
Estimated value
Report date
02 Mar 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Vaxart, Inc.

Security class
Stock Option (right to buy)
Shares / value
44,224
Estimated value
Report date
04 Aug 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Todd C. Davis

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .